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Abstract
The Epstein–Barr virus (EBV) has recently been associated with hepatocellular carcinoma (HCC) arising in Japanese patients. We
analyzed 82 cases of HCC from Germany and the U.K. for the presence of EBV DNA and viral gene products within tumor cells. Initial
screening of whole sections using quantitative (Q)-PCR detected EBV DNA in 9/58 U.K. cases and in 9/24 German cases; in positive cases
viral load was very low, ranging between 1.4 and 49.1 copies of the EBV genome/1000 cell equivalents, compared to much higher values
for EBV-positive Hodgkin’s disease and nasopharyngeal carcinoma controls (range, 714–3259/1000 cells). EBV DNA was not detected in
the tumor cells of any of the Q-PCR-positive cases either by Q-PCR of pure tumor cell populations isolated by laser capture microdissection
or by isotopic in situ hybridization. Furthermore, none of the German or U.K. HCC tumors tested positive for EBER or EBNAI expression
in tumor cells. Our results provide strong evidence that HCCs from the U.K. or Germany are not associated with EBV.
© 2003 Elsevier Science (USA). All rights reserved.
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Introduction
The association between the ubiquitous Epstein–Barr
virus (EBV) and several epithelial cancers including undif-
ferentiated nasopharyngeal carcinoma (UNPC) (Klein,
1979), a subset of gastric adenocarcinomas (Shibata and
Weiss, 1992), and lymphoepitheliomas from a variety of
sites (Iezzoni et al., 1995), is now well established. Two
recent studies have suggested the possibility that hepatocel-
lular carcinoma (HCC) might be a new addition to the list of
EBV-associated diseases. In the first of these (Sugawara et
al., 1999), monoclonal EBV DNA was detected by Southern
blot hybridization in 13/35 (37%) of HCC tumors of Japa-
nese patients, 10 of which contained EBV only in tumor
tissue and not in nontumor tissues. Staining of three tumor
specimens using human sera specific for the EBV-encoded
nuclear antigen (EBNA) complex revealed nuclear labeling
in a fraction (7–13%) of the tumor cell population. Western
blot analysis and RT-PCR detected Qp-driven EBNA1 ex-
pression and the BamH1A transcripts, but not expression of
any other latent genes, including the EBERs. This observa-
tion suggested the possibility of a novel EBER-negative
form of EBV latent infection and raised concerns regarding
the use of EBER in situ hybridization as a means of deter-
mining the EBV status of tumors. In the second study
(Sugawara et al., 2000), EBV was detected by PCR in HCC
from both hepatitis C virus (HCV)- and hepatitis B virus
(HBV)-positive patients, although EBV was present more
frequently in the HCV group.
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Definitive designation of a tumor as “EBV-associated”
requires unequivocal demonstration of the EBV genome or
virus gene products in the tumor cell population. In this
regard, PCR and Southern blotting are generally considered
unsatisfactory since, when used alone, they cannot localize
the virus to specific cell types. On the other hand, immu-
nohistochemistry for detection of essential latent proteins,
such as EBNA1, may lack specificity and sensitivity.
To overcome these difficulties, we have applied two
methods to detect the EBV genome in HCC samples from
the U.K. and Germany. In the first method we employed
real-time quantitative (Q)-PCR combined with laser capture
microdissection (LCM) to quantify EBV copy number in
tumor cells isolated from HCC samples. In the second
method we used a highly sensitive isotopic in situ hybrid-
ization method to localize EBV DNA to specific cell types.
In neither of these approaches could we detect EBV DNA in
the tumor cell population. We conclude that EBV is not
associated with HCC originating in patients from the United
Kingdom or Germany.
Results
Q-PCR assay to quantify EBV genome load and cellular
input
We used a Taqman multiplex PCR assay to simulta-
neously detect EBV Pol and cellular B2m sequences. Am-
plification of the endogenous B2m reference gene served as
a control for the input of cellular DNA. A typical Pol
amplification plot showing changes in fluorescence intensity
against cycle number from a series of Namalwa DNA dilu-
tions (105, 104, 103, 200, 40, 10, 5, and 2 EBV genomes) is
shown in Fig. 1A. A calibration curve (Fig. 1B) generated
from the same data shows a strong linear relationship be-
tween the Ct values and the log10 value of the initial EBV
copy number (r 0.99) and the dynamic range extends over
at least five orders of magnitude. We could reproducibly
detect as little as two EBV genomes using this assay, al-
though, as expected by Poisson distribution, this standard
was amplified inconsistently (data not shown). Amplifica-
tion plots for B2m obtained using the same Namalwa DNA
dilutions showed a similar sensitivity and dynamic range
(data not shown). No significant difference was seen in the
sensitivity or efficiency of the Pol and B2m amplifications
generated from Namalwa standards diluted in water or in a
background of 600 ng EBV-negative DNA (data not
shown).
Q-PCR analysis of whole sections of tumor
All cases were initially screened by Q-PCR. The EBV
genome was detected in 9/58 U.K. cases (15.5%), but in all
these cases the genome copy number was very low (range of
1.5–49.1 copies/1000 cell equivalents). Likewise, 9/24
(37.5%) of the German tumors contained low copy numbers
of the EBV genome (range 1.4–38.5 copies/1000 cell equiv-
alents). Q-PCR analysis of positive controls revealed much
higher viral loads compared with HCC specimens (Table 1).
EBV was not detectable in negative controls.
Q-PCR analysis of tumor cells isolated by LCM
The nine U.K. cases in which the EBV genome was
detected by Q-PCR of whole sections were subject to LCM
(Fig. 2) for isolation of tumor cells followed by Q-PCR.
Despite the collection of multiple tumor clusters from dif-
ferent locations, the EBV genome was not detected in any of
these samples. B2m detection revealed that adequate num-
bers of tumor cells had been sampled in all cases (Table 2).
EBV was regularly detectable in microdissected tumor cells
from EBV-positive NPC controls (Table 2).
In situ hybridization for BamH1 W repeats
All nine of the U.K. tumors and five of the German cases
that tested positive for the EBV genome by Q- PCR analysis
of whole sections were assayed by a highly sensitive in situ
hybridization assay to detect the EBV genome. All of these
Fig. 1. Detection of EBV genomes by Q-PCR. Serial dilutions of Namalwa
DNA containing 105, 104, 103, 200, 40, 10, 5 and 2 EBV genomes were
amplified using primer/probe combination specific for EBV Pol and cel-
lular B2m sequences in a multiplex PCR and the fluorescent signals
detected using an ABI Prism 7700. (a) Change in FAM fluorescent inten-
sity (Rn) plotted against cycle number; replicates are omitted for clarity.
(b) Calibration curve generated by plotting the Ct value for each sample,
defined as the fractional cycle number at which the amplification plot
crosses the threshold (solid horizontal line), against the initial number of
EBV copies. The y- intercept corresponds to the number of cycles required
to detect a single episome and was consistently less than 40 cycles.
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cases were negative despite detection of the EBV genome in
controls (Fig. 3).
EBER in situ hybridization/EBNA1 immunohistochemistry
EBER RNAs were not detected in tumor cells of any of
the nine U.K. HCC samples shown to be positive by whole-
section PCR, or in any of the 24 German tumors. By
contrast strong reactivity was seen in positive controls (data
not shown). In a single case from the U.K., isolated EBER-
positive cells in the tumor stroma were noticed (case num-
ber UK1). Immunoreactivity with the monoclonal antibody
2B4-1 and 1H4-1 was also not detectable in these tumors,
whereas control EBV-positive NPC tumors showed typical
granular nuclear staining (data not shown).
Discussion
Two studies have suggested the possibility that hepato-
cellular carcinomas may represent yet another addition to
the growing list of EBV-associated tumors (Sugawara et al.,
1999, 2000). Interestingly, in the first of these, EBNA1
Table 1
Details of samples in which the EBV genome was detected by Q-PCR of whole sections
Case/control number Number of copies
of B2m
EBV genome copy number
(assuming two copies of
B2m/diploid cell)
No. of EBV copies per
1000 diploid cell equivalents
UK1 912 11 24.1
UK2 6026 11 3.7
UK3 13,571 18 2.7
UK4 11,242 276 49.1
UK5 3465 3 1.7
UK6 2921 2 1.4
UK7 2977 6 4.0
UK8 11,758 9 1.5
UK9 37,450 76 4.1
GER1 1447 2 2.8
GER2 3163 11 7.0
GER3 1593 7 8.8
GER4 1931 2 2.1
GER5 250 2 16.0
GER6 5707 4 1.4
GER7 156 3 38.5
GER8 3934 11 5.6
GER9 251 3 24.0
NPC1 1852 1219 1316
NPC2 2261 3684 3259
NPC3 1799 2224 2472
HD1 6036 2555 847
HD2 479 171 714
Note. Included as controls are whole sections of EBV-positive NPC and HD tumors.
Table 2
Absence of the EBV genome in nine cases of HCC analysed by LCM-Q-PCR
Case/control number Number of copies
of B2m
EBV genome copy number
(assuming two copies of
B2m/diploid cell)
Copies of EBV per
diploid cell equivalent
UK1 335 0 0
UK2 767 0 0
UK3 813 0 0
UK4 711 0 0
UK5 693 0 0
UK6 364 0 0
UK7 642 0 0
UK8 1757 0 0
UK9 1659 0 0
NPC1 23 73 6.3
NPC2 43 117 5.4
Note. EBV could be regularly detected in EBV-positive NPC controls, even when only small numbers of cells were collected.
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expression and the presence of the BamH1A transcripts
were detected in the absence of EBER expression, suggest-
ing that HCC might be characterized by a unique form of
viral latency. Moreover, EBV genomes detected in this
study were shown to be monoclonal by analysis of the
terminal repeat region. This finding points to the presence of
EBV in a monoclonal cell population and implicates the
tumor cells as the likely source of the viral DNA. However,
more recently, Chu and colleagues (Chu et al., 2001) used a
variety of approaches to detect EBV in a series of American
HCCs. Although none of their 41 samples were EBV-pos-
itive by PCR for either LMP1 or EBNA4 DNA, they were
able to detect immunoreactivity for EBNA1 in the tumor
cells of two cases using the 2B4-1 monoclonal reagent and
two further cases contained BZLF1-positive or EBER-pos-
itive nontumor cells.
EBV detection in tumors has generally employed either
methods such as PCR (and RT-PCR) or Southern/Western
blotting, or in situ approaches such as immunohistochem-
istry or in situ hybridization for the detection of virus gene
products. Unfortunately, each of these approaches has sig-
nificant drawbacks; PCR and blotting methods do not rule
out the detection of EBV in nontumor cells, and in situ
methods to detect gene expression may be uninformative
where there is restricted virus gene expression. Further-
more, the reagents currently available to detect the only
essential EBV gene product, EBNA1, are not entirely spe-
cific and show low sensitivity (Grasser et al., 1994; Murray
et al., 1996; Brink et al., 2000).
Because of these methodological difficulties, we decided
to target the EBV genome for detection using two distinct
but complementary approaches. First we combined Q-PCR
with LCM to quantify EBV DNA in isolated tumor cells,
and second, we employed a highly sensitive in situ hybrid-
ization technique to detect the BamH1W repeats of the EBV
genome.
Initial screening of whole tumor sections by Q-PCR
detected EBV in a proportion of cases. Importantly, how-
ever, the copy number was very low in these cases. A
number of EBV-positive cases was then subject to micro-
dissection followed by Q-PCR. Although, B2m copy num-
ber was high in all these microdissected samples, EBV
DNA was not detectable in isolated tumor cells from any
case. Application of an isotopic in situ hybridization for
detection of viral DNA confirmed these results. In one of the
previous studies EBV was only detected (by EBNA stain-
ing) in a fraction of the tumor cell population (Sugawara et
al., 1999). We believe that sampling error during the LCM
process is unlikely to have explained our negative findings,
since multiple tumor clusters from different locations within
each tumor were analyzed.
Our study provides compelling evidence that the small
quantity of EBV that can be regularly detected during the
gross analysis of European HCC tumor tissue does not
originate from the tumor cell population. The most likely
source of this viral DNA is from EBV-infected bystander
lymphocytes; such EBV-infected lymphocytes have previ-
ously been detected in liver specimens (Niedobitek et al.,
1997). Many cases of HCC occur in a background of cir-
rhosis and chronic liver disease may itself be immunosup-
pressive. In combination with the possible application of
immunosuppressive therapy for liver disease and cancer
chemotherapy in some patients this could be responsible for
Fig. 2. Laser capture microdissection of a single cluster of tumor cells from
an HCC lesion. (a) and (b) Sections before and after capture, respectively.
(c) The microdissected cells on the Eppendorf cap after capture. In the
analysis of EBV copy number multiple tumor clusters were pooled and
analyzed by Q-PCR.
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an increase in the EBV-infected B cell pool which could be
more readily detected by whole-section PCR.
We conclude that HCC, at least from the United King-
dom or Germany, is not an EBV-associated disease. Further
studies employing robust methodologies, such as those de-
scribed here, are required to determine if EBV is associated
with HCC from other geographical locations.
Materials and methods
Tissues
Paraffin wax embedded tissue blocks from a total of 82
patients with histologically confirmed HCC were used in
this study. Fifty-eight patients were diagnosed at the Queen
Elizabeth Hospital, Birmingham, U.K. and a further 24
cases were retrieved from the files of the Pathological In-
stitute in Erlangen, Germany.
DNA extraction from whole tumor sections
For all tissues DNA was extracted from 16-m paraffin
sections using the DNeasy Tissue Kit (Qiagen Ltd., Cat. No.
69504), according to the manufacturer’s instructions. Con-
trols, also cut at the same time as test samples, included
paraffin wax embedded pellets of EBV-negative D674 cells,
the EBV-positive line, Namalwa, which is diploid and car-
ries two copies of the EBV genome (Whitaker, 1985; Law-
rence et al., 1988), as well as EBV-positive NPC and
Hodgkin’s disease (HD) specimens. Initial screening for
EBV DNA was performed using Q-PCR.
Real time Q-PCR assays
Amplification of target DNA sequences was followed by
real-time monitoring of changes in fluorescence intensity
using dual-labeled fluorogenic Taqman probes (Heid et al.,
1996). EBV DNA was detected using primers to specifically
amplify a fragment of the EBV DNA polymerase (Pol) gene
in combination with a FAM-labeled probe (Gallagher et al.,
1999). Primers for the amplification of the human beta 2
microglobulin (B2m) gene in combination with a VIC-
labeled probe were used to determine the input cellular
DNA in each sample and normalize for variations in the
number of cells taken for analysis or DNA recovery (Sum-
mers et al., 2001). All primer and probe sequences (Table 3)
were obtained from PE Biosystems. EBV Pol and control
B2m sequences were detected simultaneously using a mul-
tiplex PCR, in which the B2m amplification reaction was
primer limited so as to avoid depletion of PCR reagents.
Amplification reactions were performed in 50 l volumes
containing 25 l Taqman Universal master mix (PE Bio-
systems), 0.5 l forward and reverse Pol primers (20 M),
1 l 5 M FAM-labeled Pol probe, 1 l 3 M B2m forward
primer, 1 l 4 M B2m reverse primer, 0.5 l 5 M
VIC-labeled B2m probe, 10.5 l water, and 10 l test DNA.
Following activation of the uracil-N-glycosylase (2 min at
50°C) and the Amplitaq Gold (10 min at 95°C), the reaction
mixtures were amplified for 40 cycles (15 s at 95°C, 60 s at
60°C) and the fluorescent signals generated by each sample
detected using an ABI Prism 7700 Sequence Detection
System (PE Biosystems).
Analysis of Q-PCR data
Changes in FAM and VIC fluorescence intensity (corre-
sponding to amplification of Pol and B2m, respectively)
were plotted against cycle number using the Sequence De-
tection Software v1.63 and the resultant amplification
curves used to determine the corresponding Ct value for
each sample, defined as the fractional cycle number at
which the amplification curve crosses a threshold level (set
as 10 times the standard deviation of the baseline). Since
this Ct value is proportional to the initial amount of starting
material, the number of Pol and B2m copies in the test
samples could then be deduced from suitable standard
curves. The Pol calibration curve was obtained from the
amplification of serial dilutions (in water) of Namalwa
DNA containing 105, 104, 103, 200, 40, 10, 5, and 2 Pol
copies (assuming diploid Namalwa cells carry two EBV
genomes and that each cell contains 6.6 pg DNA); a linear
calibration curve was then generated by plotting Ct values
(y-axis) against log10 Pol copy number (x-axis) from which
the initial number of EBV genomes in the unknown samples
could be determined. Similarly a B2m calibration curve was
generated from the same Namalwa DNA dilutions and used
to determine the cell input in each sample (assuming two
B2m genes per diploid cell).
All standards and test samples were analyzed in dupli-
cate (10, 5, and 2 copy number standards were run in
triplicate). Each experiment included DNA samples pre-
pared from EBV-positive and EBV- negative controls, as
well as water-only (no template) controls. Samples were
considered negative if the Ct values exceeded 40 cycles.
Laser capture microdissection
All U.K. cases identified to contain the EBV genome by
Q-PCR analysis of whole sections were subject to LCM
Table 3
Primer and probe sequences
EBV polymerase gene
Forward primer: 5 AGT-CCT-TCT-TGG-CTA-GTC-TGT-TGA-C 3
Reverse primer: 5 CTT-TGG-CGC-GGA-TCC-TC 3
Dual-labeled fluorogenic probe: 5 (FAM) CAT-CAA-GAA-GCT-GCT-
GGC-GGC-CT (TAMRA) 3
Beta-2 microglobulin gene
Forward Primer: 5 GGA-ATT-GAT-TTG-GGA-GAG-CAT-C 3
Reverse Primer: 5 CAG-GTC-CTG-GCT-CTA-CAA-TTT-ACT-AA 3
Dual-labeled fluorogenic probe: 5 (VIC)-AGT-GTG-ACT-GGG-CAG-
ATC-ATC-CAG-CTT-C (TAMRA) 3
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Fig. 3. In situ hybridization for the detection of EBV DNA using a 35S-labeled probe reveals the presence of the virus in most cells of the B95.8
lymphoblastoid cell line (A). Using in situ hybridization with 35S-labeled RNA probes, expression of the EBERs is detected in the vast majority of B95.8
cells (B). Similarly, expression of EBNA1 is detected by immunohistochemistry in most B95.8 cells (C, red labeling). Application of these methods to
hepatocellular carcinomas reveals absence of viral DNA from the tumour cells (D) and lack of expression of the EBERs (E) or EBNA1 (F) in the epithelial
tumor cells. Note a few EBER-expressing lymphoid cells in the tumor stroma of a hepatocellular carcinoma in E.
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followed by Q-PCR: Sections measuring 4 m were cut
onto uncoated slides, taken to water, and stained in hema-
toxylin. This was followed by thorough dehydration and
two washes in xylene. LCM was performed on dry sections
using the PixCell II system (Arcturus Engineering Inc.
Mountain View, CA). Multiple individual clusters of tumor
cells from different regions of each tumor were microdis-
sected (Fig. 2) and pooled onto the same cap. Clusters of
tumor cells containing prominent lymphocytes or other non-
malignant cells were not collected. DNA was extracted from
LCM-procured tumor cells using the LCM/DNA extraction
kit (Arcturus Ltd.) or the DNeasy kit (Qiagen Ltd.).
Isotopic in situ hybridization
All U.K. and German cases identified as PCR-positive by
whole-section PCR were investigated using an isotopic in
situ hybridization method to detect EBV DNA provided
sufficient tissue was left in the block. The plasmid pBS-W
harboring the BamHI W fragment of the EBV genome was
labeled with [35S]dCTP (1200 Ci/mmol, NEN Life Science,
Cologne, Germany) by nick translation using a commer-
cially available kit (Amersham, Braunschweig, Germany).
In situ hybridization was carried out as described previously
(Niedobitek et al., 1991). Controls were pelleted paraffin
embedded B95.8 cells and these served as surrogates for
clinical samples containing latent EBV episomes. In brief,
paraffin sections were dewaxed, rehydrated, treated with 0.2
N hydrochloric acid and pronase (0.5 mg/ml, Boehringer,
Mannheim, Germany), acetylated in 0.1 M triethanolamine
pH 8.0, 0.25% (v/v) acetic anhydride, dehydrated through
graded ethanols, and air dried. An amount of 25 l of
hybridization mixture (50% deionized formamide/2 SSC/
10% dextran sulphate/100 g/ml carrier DNA/10 mM
DTT/1 ng labeled probe) was added per slide. Tissue and
probe DNA were simultaneously denatured at 95°C for 2
min, followed by hybridization at 37°C overnight. Subse-
quently, slides were washed in 50% formamide/2 SSC/10
mM DTT at 37°C for 4 h, dehydrated through graded
ethanols, air dried, and dipped in Ilford G5 photographic
emulsion. Slides were stored at 4°C for 3 to 12 days,
developed, fixed, and counterstained. This method was pre-
viously shown to detect a single copy of the EBV genome
in AW Ramos cells (Niedobitek et al., 1991).
Immunohistochemistry for EBNA1
In parallel, immunohistochemistry was performed for
detection of EBNA1 protein on all German cases and on all
U.K. cases in which Q-PCR of whole sections detected
EBV. Briefly, sections were taken to water and endogenous
peroxidase activity blocked in 3% hydrogen peroxide/meth-
anol, prior to microwave antigen retrieval in citric acid
buffer pH 5.8 for 50 min at full power (750 W). Following
an endogenous biotin-blocking step (Dako Ltd., Cat No.
X0590), sections were incubated in monoclonal antibody
reactive against EBNA1 (either 2B4-1 or 1H4-1, gifts from
E. Kremmer) for 1 h at RT. After a brief wash in TBS pH
7.6, mouse anti-rat antibody (Dako Ltd., Cat No. E0468)
was then applied for 30 min prior to detection using the
StreptABComplex/HRP duet mouse/rabbit kit (Dako Ltd.,
Cat No. K0492.). Visualization was by the standard diami-
nobenzidine reaction.
EBER in situ hybridization
In situ hybridization for EBER-1 and EBER-2 was also
carried out on those U.K. cases identified as EBV DNA
positive by whole-section Q-PCR and on all German cases.
Digoxigenin- or 35S-labeled probes were prepared by in
vitro transcription of recombinant plasmids (pBSJJJ1 for
EBER-1 and pBSJJJ2 for EBER-2) in the presence of
digoxigenin- or 35S-labeled nucleotides (Niedobitek et al.,
1991). Sense probes and known EBV-positive and -negative
controls were included in all runs.
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